The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy-Reference-Cited by-同舟云学术

The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy

Published:2020-03 Issue:3 Volume:294 Page:647-657
ISSN:0033-8419
Container-title:Radiology
language:en
Short-container-title:Radiology

Author:

Kinahan Paul E.^ORCID,Perlman Eric S.,Sunderland John J.,Subramaniam Rathan^ORCID,Wollenweber Scott D.^ORCID,Turkington Timothy G.^ORCID,Lodge Martin A.^ORCID,Boellaard Ronald^ORCID,Obuchowski Nancy A.^ORCID,Wahl Richard L.^ORCID

Funder

National Institute of Biomedical Imaging and Bioengineering

Publisher

Radiological Society of North America (RSNA)

Subject

Radiology Nuclear Medicine and imaging

Link

http://pubs.rsna.org/doi/pdf/10.1148/radiol.2019191882

Reference41 articles.

1. Quantitative Imaging: The Translation from Research Tool to Clinical Practice

2. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

3. Recommendations on the Use of 18F-FDG PET in Oncology

4. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

5. Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 18F-FDG-PET/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors;Academic Radiology;2024-09

2. Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence?;Journal of Nuclear Medicine;2024-08-14

3. The impact of introducing deep learning based [18F]FDG PET denoising on EORTC and PERCIST therapeutic response assessments in digital PET/CT;EJNMMI Research;2024-08-10

4. Evaluations of an Early Change in Tumor Pathophysiology in Response to Radiotherapy with Oxygen Enhanced Electron Paramagnetic Resonance Imaging (OE EPRI);Molecular Imaging and Biology;2024-06

5. The development process of ‘fit-for-purpose’ imaging biomarkers to characterize the tumor microenvironment;Frontiers in Medicine;2024-05-16